{"name":"Ashvattha Therapeutics, Inc.","slug":"ashvattha-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"D-4517.2","genericName":"D-4517.2","slug":"d-4517-2","indication":"Other","status":"phase_2"},{"name":"18F-OP-801","genericName":"18F-OP-801","slug":"18f-op-801","indication":"Other","status":"phase_1"},{"name":"MGB 600 mg","genericName":"MGB 600 mg","slug":"mgb-600-mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"D-4517.2","genericName":"D-4517.2","slug":"d-4517-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"18F-OP-801","genericName":"18F-OP-801","slug":"18f-op-801","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MGB 600 mg","genericName":"MGB 600 mg","slug":"mgb-600-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOZkpoOHZJTjRkbXVuWFhqZXVEMWM0b2pzaHQ3dTFZQWFQR3YxUVVzLU8ya2JEbEhKVjEtenMwb20xSDNfRE1tMTd0Qlg0bGROVmdyVURTQjM0STg3Q195aC1zVjJSbnFlR3FOd29PTm8ybGNGWGpkTFd0WERhek1scDEtc1JmUDdkVWxGendmd1Nnbklv?oc=5","date":"2026-03-12","type":"regulatory","source":"openPR.com","summary":"Diabetic Macular Edema Treatment Pipeline Shows Strong - openPR.com","headline":"Diabetic Macular Edema Treatment Pipeline Shows Strong","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNMENtcHdwbm5uRFlkLWNJX1BraGxlTllhanQxSUhDMEM3emtTWTRzbTFXU0FGYnlnMVVFdDZick1WM1ZLWmwtSzJYdjhoM1lyY1pkdDNiaWxTS1FwcXg4NGNpcExPeWFDa3NCaEwybW1FQWgta2IyV1hqZjBPMzVUd3JMejNkeFZxajU5NTZQYlJwam15ZEZLa2l4NTFUMFB4U1drdDU2QXJQT2phU3I4aVUzbHY1TVJkYVhFT3N5WUJtSjQ0YzVtbm15VjdaLW5U?oc=5","date":"2025-11-21","type":"pipeline","source":"Clinical Leader","summary":"Ashvattha Therapeutics Shows Real-World Focus With subQ Bilateral Dosing For Ophthalmology Drug - Clinical Leader","headline":"Ashvattha Therapeutics Shows Real-World Focus With subQ Bilateral Dosing For Ophthalmology Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOdkVfeHRndnNTODdCSHRubXpwY2xvaWJ4UWxsZDd5cl96RHFNTzkwUnYzZ3V1TGJLbnU4ZWswZGNqR0dGUTZzdEhmOWRnZWdTb0F5bW1aQ01UOUxFZmg3T0lINThzUjZmcGtWbktJaGVTSjlzY1M3UXhzbjJYdDhtTWNOOE9YNkRka2JfWmZFbTVDbVZjZkhZT0paYmQybzc0bURZdmFBVUNES0U?oc=5","date":"2025-10-17","type":"pipeline","source":"Fierce Biotech","summary":"Cabaletta corrals cell therapy Legend—Chutes & Ladders - Fierce Biotech","headline":"Cabaletta corrals cell therapy Legend—Chutes & Ladders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9vRmJsZ1NIQ2dWRGJZQ0JNakc2ckxpYjVod2x3RXNIN1Q3Y3c0Q0VrSVdGR0tQd2VXbzlScm9yeXd6Vl9DR1duZjNZTkRvWTNtSXlldmVrbmY3SHhuMEFLNjAzNWRGckhWaUwtZWpUWlM2cVFlUUpiWkNqTDg?oc=5","date":"2025-10-15","type":"pipeline","source":"BioCentury","summary":"Pruzanski named CEO of Alentis - BioCentury","headline":"Pruzanski named CEO of Alentis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPMm96elBZMVMyM0ZOSll4X3hZTzNGdHNoNkF5eXFxM04xemRsMG9sX2hFTzZsdi05LU1OU09rTk1keUNiazJGTnY4MWRyNTFWbWJ2T1ppdWN1VDFRM2RhMHV1Y2ZWakhBQ2lSWWtuaUVjSHByUzJjc3NOWkFxQnpwV3ppempYckJac3ZkUVNwQzBDbmJ3cVZhdWdqWE1laDhFUl85Y2hUcVFERFFXOGF6ZlVMM2pWQQ?oc=5","date":"2025-06-06","type":"pipeline","source":"Clinical Leader","summary":"When CRO Selection Went Sideways, Ashvattha Therapeutics Did This To Recover - Clinical Leader","headline":"When CRO Selection Went Sideways, Ashvattha Therapeutics Did This To Recover","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNR3NmM1NMaWZUY3gyLWdNVldPTFRuRXBfT3dvSnowcXp3MUxqMGs0Um5KVV9RMEMwUEc5TmlMRFFodzhjQVY5aGZ2anNjMmg0WW15R2lUbkFKVUJDekdfMnpJODNIQlpabDl4QVBRaGpsOHd2aGtsN0ZRVC16dXN1N25ENmJBSU1RMnlNTzl3TTlBQUVmTmthNktERnhjeDN1dU44QVVsVzYwNWMzTVE?oc=5","date":"2025-04-30","type":"pipeline","source":"Ophthalmology Times","summary":"Companies announce presentations at upcoming 2025 ARVO Annual Meeting - Ophthalmology Times","headline":"Companies announce presentations at upcoming 2025 ARVO Annual Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE9yNjRnVXFhS0NNdHNxZGhYeXpMa1lxZzl0LW84TkRsNjRaZUhaN1hVUUxVTVVNaVg4dXVBYnlsb21SS0pkQWZJWFd5VFRFcEJrdmhfVkY4T1dpdDFmcUpRdFVway0?oc=5","date":"2025-03-15","type":"pipeline","source":"The Pharma Letter","summary":"Ashvattha Therapeutics - The Pharma Letter","headline":"Ashvattha Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gJBVV95cUxNR3JCQnhRWFJKakk0Ykwxd25Za2xkR2lvY1ZPbGNUR29BaDZiaHZ5TWRZbmxUUm9RaXNPWFNjaFduVUw5NHBZRmZWQ01KYnUwNlVlRzg3UFVZcWJ4eFpzNHk1VGZLNDd4OWwzUllQRkIyZFNsVzB5UDBNd3Q3OGFMQllCR2NDczdtaXhETmhhM0swQ2oxT1NRRnlvdkRQbzRGLWFJX3BqTXRXcHQya3ctdFJEYlc0YlAwdFo0bW1TMFNTQUhSb01scmI2SFYwN3RISDhRUU9yazBLWklLMU9nbEJINGdaa3QtdTh3d0dYdHVnY3R1b2FEZDFWcGk2YkdqX25yOVVNUC1xOVRVWDVKcl80NGgwc0ZwZW9MLUJLYjFmWkl6T1NOT1hXQ1h4eVlNNTVLVU9pWDB4bFBLVUdiSEMzT0wyZ0ZVMERyTmdYanlXWGhwbGc?oc=5","date":"2024-11-13","type":"trial","source":"GlobeNewswire","summary":"NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears - GlobeNewswire","headline":"NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQaXJtWXdOWkRiUzVlSE5zNzJubWFQUkExa1Vwb0xpdjQ5TjAxQ3FaN09RRzl1dWM5a2U2aWNNRmJFWFVWcTBUelFKSmZISmlzMm5MeTdJZy13MWdkdGRiTEM5UjlzNW5tU2k4SUZLRUpZLWZsTkpwamdmRE9PQzhmRk5xbkJIaTVwWE9lZ3RvVHZjQXp5bURQRmZHYkRXd0w5SUIxb0RvM1RzNFlnVXVEVGE1VnJIZHNlaHh2M2tIWVpVVGxNQTc3SHhDSEhiQ3RQU1NENGFGdw?oc=5","date":"2024-01-28","type":"pipeline","source":"Ophthalmology Times","summary":"President and CEO of Ashvattha Therapeutics talks about the company's unique nanomedicine technology - Ophthalmology Times","headline":"President and CEO of Ashvattha Therapeutics talks about the company's unique nanomedicine technology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNZDFXaVdBUTkxZjcwY2FMb2QtTTFHWE1tUl9icDdVZkJJYlRXYjdrXzd1aE1ZNXNfdXJfeFBrR3lxRFZjdzNya3pmWV9tdnVYUC1mbktFazJKa0VCNTk4VGRKS0ZvRmVqclp3dTEtUjl4TTRqQ3hZWHlqNVo1WjNwekIxOUJ2bU83dkROX0xuX0RxUjFIcFY3ZmgtakszdkJRd2pCSks2Uk1MYUhibmc?oc=5","date":"2022-05-16","type":"deal","source":"Pharmaceutical Technology","summary":"These were the biggest pharmaceutical deals in early 2022 - Pharmaceutical Technology","headline":"These were the biggest pharmaceutical deals in early 2022","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":1,"phase_1":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}